Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
That was Synairgen plc, not Synairgen Research Ltd. A minor technical point.
Just to add - these are possibilities in addition to going it alone, at least for initial covid-19 sales, which I didn’t list.
At least we got a mention as part of ACTIV-2. Nothing much.
Testimony before the United States Senate Committee on Health, Education, Labor, and Pensions by Anthony S. Fauci, July 20, 2021.
https://www.help.senate.gov/imo/media/doc/Fauci10.pdf
In a rather belated manner it dawned on me that the patents to SNG001 belong to Synairgen Research Ltd and all of the trials, including ACTIV-2, are conducted in the name of Synairgen Research Ltd which in turn is wholly owned by Synairgen plc.
So if SGN001 is proven to be an efficacious treatment for covid-19 an alternative to a takeover would be for Synairgen plc to sell Synairgen Research Ltd. It would be a much simpler transaction than the takeover of the public entity i.e. Synairgen plc and I’m sure a buyer would prefer this simpler option.
Of course a licensing deal is a possibility too which seems to be the favoured route.
From what I can make out the LOXL2 royalties agreement was signed with Synairgen plc so that would not be affected by the sale of Synairgen Research Ltd.
Up to seven sites.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004743-83/DE
Germany is onboard since beginning Jul.
Clinigen or Synairgen cannot push i.e. promote SNG001 under MAP. Not allowed to.
And before anyone says anything again about an EUA remember it cannot be granted unless Synairgen applies for it.
*seems like 2 & 3 are the same.
I must say we kicked Reddit’s a** (again)! Hahahaha
I do like a bit of competition :-)
ac19 - I think they may have completed the form incorrectly. From those names I get these hospitals
1) Eme Red Hospitalaria
2) Hospital Bernardo J Gastelum
3) General Hospital of Culiacán ( same city as no 2)
4) Unknown - Monterey is a city in the region of Nuevo León. Different region to hospitals in 1, 2 & 3. So we must have one here too.
40 patients are too many for just one or two hospitals.
Anyway, most importantly we’re up and running.
Again thank you for looking into those weblinks for me!!
Kiwi10 - thx for trying!
ac19 - that’s brilliant! Thank you! So these two are both hospitals.
1) Eme Red Hospitalaria
2) General Hospital of Ciuliacan.
To confirm the following two are both hospitals too right?
3) Monterey, Nuevo Leon
4)Dr Bernardo J Gastelum
And, does it give the status of recruitment?
Trying to look for any clues as to the status or non status of SG018 in Mexico, although I get a feeling it's not happening. The below two links should take you to Mexico's trial registry, but I can't access them. It just says 'The site can't be reached'. Anyone located in the States maybe or with a VPN who'd like to try?
http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicos.asp
http://siipris03.cofepris.gob.mx/RegNacEnsClinicos/
Mikep109 - agree on serious illness. I run an analysis to compare the infection rate per 100k vs the hospitalisation rate per 100k for England only. As of 06 Jul the infection rate was roughly 302 per 100k with a comparable hospitalisation rate of about 6.4. (Note to ensure the data is comparable I would use infection rates as of 06 Jul and hospitalisation rate of 13 Jul - seven day lag.)
If you compare that to the infection rate range of between 280 to 320, which was for the period Nov 2020 to Jan 2021, the comparable hospitalisation rates were between 24 to 30.
Joey - not sure if there’s a readily available report. You can always try and create your own one if such metrics are available. You should use the link below.
https://coronavirus.data.gov.uk/details/download
Doc - I really don't know the answer to that. They may have been able to address the limited supply issue and I hope they did, but there is no way of knowing. All I was trying to say was that one should be cautious in the interpretation of new sites being added when it comes to phase II.
New sites being added may not benefit SNG001 during phase II because of the below quote from the ACTIV-2 master protocol. The extend to which this was a limitation is unknown, however seeing we still don't have any news on progression is potential evidence that it may have been a factor slowing down recruitment. I would therefore urge caution so to not read too much into it.
Quote: 'Participation in phase II evaluations of this agent will be restricted to select US sites, due to limited
investigational agent/placebo supply.'
Here’s some reading material supporting SNG001’s method of delivery. Just found it so have not ready further than the intro, but at least it’s out on the BB.
‘Since the route of infection and disease progression is primarily through the lungs, the inhalation delivery of drugs directly to the lungs is the most appropriate route of administration for treating COVID-19. The International Society for Aerosols in Medicine (ISAM) has also called for the development of inhaled therapies for COVID-19 treatment because the symptoms of COVID-19 are mainly manifested in the respiratory system [9].’
https://res.mdpi.com/d_attachment/pharmaceutics/pharmaceutics-13-01077/article_deploy/pharmaceutics-13-01077.pdf
Here’s a re-post of my earlier post which had its thread removed.
?Another covid-19 patent was filed by Synairgen on 27 Apr 2021 in addition to the two from Jul 2020.
https://patents.google.com/patent/GB202106014D0/en?assignee=synairgen&after=priority:20200101
Here are all three pending covid-19 patents. Due to their pending status you can’t see any detail yet other than the application header.
https://patents.google.com/?q=sars-cov-2&assignee=synairgen&after=priority:20200101
Plus, I found the below article with regards to the firm who assisted Synairgen. Basically this led me to discover the third patent application.
https://www.hgf.com/news/iam-1000-2021/
HGF is a leading European IP firm.
Quotes from the article.
IAM Patent 1000 is a unique guide that identifies the top patent professionals in key jurisdictions around the globe. It shines a spotlight on the firms and individuals that are deemed outstanding in this pivotal area of practice.
HGF is delighted to have 18 European attorneys listed within the latest IAM Patent 1000 guide from our offices in the UK, Scotland, The Netherlands, Germany and Ireland.
”The twin pillars on the life sciences side are Andrew Wells and Claire Irvine. Chemistry head Wells holds a PhD in vaccinology and also worked in-house at a multinational pharmaceutical giant; while “fearless warrior” Irvine lately played a vital role in securing patents for the use of Synairgen’s Interferon-beta drug to combat the respiratory symptoms of covid-19. “Claire pays meticulous attention to detail and has superb technical and scientific knowledge. Clients can concentrate on their own growth, knowing their IP is in safe hands.”
Woodstock1970 - Masks are not required in outdoor spaces due to free air flow i.e. ventilation.
Stop ranting & complaining. It won’t better your life. It’s defeatist.
And re the EUA - no Health Authority is going to approve a drug based on a trial of 86 patients (excl those who withdrew).
There’s no need to post whatever pops up in your mind.
It is simply disrespectful to discredit someone’s contribution of a factual piece, reported not only by the BBC, by rubbishing the news outlet it was reported by.
*experienced
SNG001 would be too expensive to use as a prophylactic especially when faced with a respiratory virus. It's not as easy to know when to administer it, whereas with HIV it's a lot easier. And, so it'll be quite expensive to just dish it out; even just to high risk patients as we've seen from the Home Trial only a small percentage experience marked or severe breathlessness. If SNG001 was similar to First Defense and in the same price range then definitely it could've been used as one I'd think.